Get Live Data

Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. GSK

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,983.50    33.50 (1.72%)
Bid:
1,984.00
Ask:
1,985.00
Spread: 1.00 (0.05%)
Market Cap: £79.47b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

GSK

11 Jul 2022 17:30

RNS Number : 0768S
FTSE Russell
11 July 2022
 

 

 

GSK (UK): Demerger of Haleon (UK)Changes in FTSE UK Index Series

11 July 2022

Further to the FTSE Russell notice released 15 June 2022 and subject to the completion of the demerger of Haleon (UK, non-constituent) from GSK (UK, constituent), please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE 100 Index

18 July 2022

FTSE 350 Index

18 July 2022

FTSE All-Share Index

18 July 2022

FTSE 350 Higher Yield Index

18 July 2022

Techmark All Share Index

18 July 2022

FTSE UK Dividend + Index

18 July 2022

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 6441 1440

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2022 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FTSQFLFFLDLBBBF
8910111213141516
Date   Source Headline
11th Sep 20243:30 pmRNSChange of Registered Office
11th Sep 20247:00 amRNSUpdate on phase I/II therapeutic HSV vaccine trial
9th Sep 20242:30 pmRNSDepemokimab late-breaking data presented at ERS
6th Sep 20243:30 pmRNSDirector/PDMR Shareholding
6th Sep 20247:00 amRNSPositive Phase III results for Nucala in COPD
2nd Sep 20243:00 pmRNSTotal Voting Rights
29th Aug 20247:00 amRNSEMA approval on Arexvy for 50-59 at risk
28th Aug 20247:10 amRNSSENKU Designation for Bepirovirsen in Japan
28th Aug 20247:05 amRNSNucala approved in Japan for use in CRSwNP
28th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st Aug 20243:30 pmRNSDirector/PDMR Shareholding
20th Aug 20243:30 pmRNSDirector/PDMR Shareholding
20th Aug 20247:00 amRNSB7-H3 ADC US FDA Breakthrough Therapy Designation
16th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
12th Aug 20243:30 pmRNSDirector/PDMR Shareholding
6th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
2nd Aug 20247:00 amRNSFDA Expands Jemperli Approval
1st Aug 20243:00 pmRNSTotal Voting Rights
31st Jul 20247:00 amRNS2nd Quarter Results
29th Jul 20248:18 amRNSStatement: Zantac (ranitidine) litigation
29th Jul 20247:00 amRNSCHMP positive opinion on Arexvy for 50-59 at risk
19th Jul 202410:36 amRNSBlenrep EMA Filing Acceptance
18th Jul 20243:30 pmRNSDirector/PDMR Shareholding
16th Jul 20243:30 pmRNSDirector/PDMR Shareholding
15th Jul 20243:30 pmRNSDirector/PDMR Shareholding
12th Jul 20243:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20247:00 amRNSGSK and CureVac collaboration restructured
1st Jul 20243:00 pmRNSTotal Voting Rights
28th Jun 20245:37 pmRNSStatement: Zantac (ranitidine) litigation
24th Jun 20247:05 amRNSOmjjara approved in Japan for myelofibrosis
24th Jun 20247:00 amRNSEMA validates Jemperli marketing authorisation
21st Jun 20243:30 pmRNSDirector/PDMR Shareholding
12th Jun 20243:30 pmRNSDirector/PDMR Shareholding
11th Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
10th Jun 20246:27 pmRNSStatement: Zantac (ranitidine) litigation
10th Jun 20247:00 amRNSFDA approves Arexvy for adults 50-59 at risk
3rd Jun 20243:00 pmRNSTotal Voting Rights
3rd Jun 20241:03 pmRNSUnprecedented results in Jemperli trial continue
3rd Jun 20247:05 amRNSASCO positive Blenrep DREAMM-8 trial results
3rd Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
24th May 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st May 20247:00 amRNSPositive phase III asthma results for depemokimab
20th May 20243:30 pmRNSDirector/PDMR Shareholding
17th May 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th May 20244:42 pmRNSGSK announces intention to sell shares in Haleon
14th May 20243:30 pmRNSDirector/PDMR Shareholding
13th May 20243:00 pmRNSBlock listing Interim Review
8th May 20246:21 pmRNSResult of AGM
8th May 20244:57 pmRNSBoard Committee Change
3rd May 20243:30 pmRNSDirector/PDMR Shareholding
8910111213141516

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
BUT
Brunner Inv.tst
LSE
0.54%
OIG
Oryx International Growth
LSE
-0.40%
HEAD
Headlam
LSE
-5.76%
SNN
SNN.L
LSE
0.00%
CVH
CVH.L
LSE
0.00%
Trending
MAC
Marechale Cap.
LSE
3.70%
TLW
Tullow Oil
LSE
2.62%
MPL
Mercantile Ports & Logistics
LSE
55.17%
PANR
Pantheon Resources plc
LSE
-3.20%
ZEN
Zenith Energy
LSE
-5.00%